cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Regeneron Pharmaceuticals Inc
175 own
47 watching
Current Price
$783.13
$31.93
(4.25%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
85,204.54M
52-Week High
52-Week High
789.95
52-Week Low
52-Week Low
538.01
Average Volume
Average Volume
1.45M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
9.957
iconMarket Capitalization85,204.54M
icon52-Week High789.95
icon52-Week Low538.01
iconAverage Volume1.45M
iconDividend Yield--
iconP/E Ratio9.957
What does the Regeneron Pharmaceuticals Inc do?
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children's. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. The company also develops EYLEA, trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma. Regeneron Pharmaceuticals, Inc. has collaboration agreement with Sanofi for the development of antibody-based clinical products comprising Praluent, Sarilumab, Dupixent, REGN2810, REGN3500, and REGN3767; Bayer HealthCare LLC for the development of Nesvacumab/aflibercept, which is used in ophthalmology; and with Teva and Mitsubishi Tanabe Pharma Corporation for developing Fasinumab, an antibody to nerve growth factor, as well as collaboration agreement with Intellia Therapeutics, Inc., to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Read More
How much money does Regeneron Pharmaceuticals Inc make?
News & Events about Regeneron Pharmaceuticals Inc.
Globe Newswire
1day ago
Fourth quarter 2022 revenues decreased 31% to $3.41 billion versus fourth quarter 2021; excluding REGEN-COV and RonapreveTM(a)(b), revenues increased 14%Full year 2022 revenues decreased 24% to $12.17 billion versus full year 2021; excluding REGEN-COV and Ronapreve(a)(b), revenues increased 17%...
Globe Newswire
5days ago
Dupixent (dupilumab) approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitis Approximately 60% of patients aged 12 years and older treated with Dupixent 300 mg weekly in the pivotal trial experienced histological disease remission; patients also...
Globe Newswire
5days ago
Approximately 60% of patients aged 12 years and older treated with Dupixent 300 mg weekly in the pivotal trial experienced histological disease remission; patients also significantly improved their ability to swallow compared to placebo Dupixent is now an option for the approximately 50,000 adults ...
Globe Newswire
8days ago
Dupixent (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis If approved, Dupixent would be the first and only targeted medicine in the EU for these young childrenRecommendation based on a Phase 3 trial in children 6...
Globe Newswire
8days ago
If approved, Dupixent would be the first and only targetedmedicine in the EU for these young children Recommendation based on a Phase 3 trial in children 6 months to 5 years old showing Dupixent improved skin clearance, reduced overall disease severity and improved health-related quality of life In ...
Frequently Asked Questions
Frequently Asked Questions
What is Regeneron Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Regeneron Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Regeneron Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Regeneron Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Regeneron Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Regeneron Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Regeneron Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Regeneron Pharmaceuticals Inc?
plus_minus_icon
What percentage is Regeneron Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Regeneron Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$783.13
$31.93
(4.25%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
GSK PLC-SPON ADR.
GSK PLC-SPON ADR.
$34.83
$-0.30 (-0.85 %)
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
$301.02
$-2.76 (-0.91 %)
United Therapeutics Corporation
United Therapeutics Corporation
$252.80
$-6.68 (-2.57 %)
Zoetis Inc.
Zoetis Inc.
$167.80
$-3.20 (-1.87 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
GSK PLC-SPON ADR.
GSK PLC-SPON ADR.
$34.83
$-0.30 (-0.85 %)
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
$301.02
$-2.76 (-0.91 %)
United Therapeutics Corporation
United Therapeutics Corporation
$252.80
$-6.68 (-2.57 %)
Zoetis Inc.
Zoetis Inc.
$167.80
$-3.20 (-1.87 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00